Leadership & Pay ·
Adial Pharmaceuticals announced that its current President and CEO Cary Claiborne and CFO Vinay Shah will be…
ADILAzora Therapeutics, Inc. (DE)
Adial Pharmaceuticals announced that its current President and CEO Cary Claiborne and CFO Vinay Shah will be terminated effective after the September 17, 2026 Annual Meeting if specific stockholder proposals are approved. Upon termination, they will receive severance per their employment agreements. Chief Development Officer Matthew Davidson is slated to become President and CEO, with a new CFO to be appointed. The filing also sets the annual meeting date for September 17, 2026, and establishes August 23, 2026 as the deadline for stockholder proposals. This corporate governance restructuring involves significant leadership changes contingent on shareholder approval at an upcoming vote. Adial Pharmaceuticals operates in the pharmaceutical industry, focusing on developing treatments for gastrointestinal disorders.